Cellectar Biosciences, Inc.

Delivering the
Next Generation
of Targeted
Cancer Therapies

Advancing Cancer Care
With Precision and Purpose

At Cellectar, we are developing precision medicine and personalized cancer treatments using our novel and validated Phospholipid Drug Conjugate Phospholipid Drug Conjugate (PDC)™ platform which possesses  the capacity to deliver a broad array of targeted oncology therapeutics.

Learn About Us

News Room

View All News
View All News

Our Science

Our unique, cutting-edge tumor-targeting technology provides optionality to selectively deliver a broad array of therapeutic modalities, including radioisotopes, small molecule cytotoxins and biologics to tumor cells by targeting lipid rafts in the plasma membranes of cancer cells. This may result in maximum antitumor activity with minimal off-target effects.

View our pipeline View our clinical trials

Lead Candidate:
Iopofosine I 131

Iopofosine is a first-in-class Phospholipid Drug Conjugate (PDC)™ designed to provide targeted delivery of iodine-131 directly to cancer cells while limiting exposure to healthy cells.

Learn More About Iopofosine

Have Questions?

Want to stay informed about Cellectar news?
Contact a Member of Our Team Sign Up for Email Alerts